Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients. - Abstract - Europe PMC
Puma Biotechnology und Pierre Fabre schließen exklusiven Lizenzvertrag zur Entwicklung und Vermarktung von NERLYNX® (Neratinib) in Europa ab | Business Wire
International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus – Assessment by a German Group of Experts - FullText - Breast Care 2020, Vol. 15, No. 1 - Karger Publishers
USA: Neues Medikament soll vor Brustkrebs-Rezidiv schützen | PZ – Pharmazeutische Zeitung
Brustkrebs-Pharmazeutika Aktien - Trendlink
Neratinib: Vorerst keine Zulassung in Europa | PZ – Pharmazeutische Zeitung
Advanced Breast Cancer
Frühes Mammakarzinom: Aktuelle Strategien in der System- und Radiotherapie | SpringerLink
Frühes Mammakarzinom: Aktuelle Strategien in der System- und Radiotherapie | SpringerLink
Mammakarzinom: Update 2019
International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus – Assessment by a German Group of Experts - FullText - Breast Care 2020, Vol. 15, No. 1 - Karger Publishers
Ergebnisse der CONTROL-Studie zeigen eine verbesserte Verträglichkeit von NERLYNX® (Neratinib) mit allen untersuchten Durchfall-Prophylaxe-Strategien
Neratinib – Wikipedia
PDF) 4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017: ABC4 Consensus: Assessment by a Panel of German Experts
PUMA BIOTECHNOLOGY INC : Kurs Aktie Börse | US74587V1070 | MarketScreener
Neratinib (Nerlynx) • Arznei-News
Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients. - Abstract - Europe PMC
Update Breast Cancer 2021 Part 3 - Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. - Abstract - Europe PMC
ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019 ABC5 – Internationale Konsensuskon
